LEXX

Announcements

Nothing here yet

Daily updates

• Lexaria highlighted oral GLP-1 therapies as a major commercial opportunity for its DehydraTECH delivery technology, which is being evaluated internally and with industry partners.Oct 6, 2026
• Lexaria partnered with PegBio to evaluate DehydraTECH oral delivery of a GLP-1 moleculeAug 14, 2026

FDA designations

Nothing here yet

News

• Lexaria praised Eli Lilly’s approval of Foundayo drugApr 7, 2026
• Lexaria's Phase 1b GLP-1 study reaches important 'last patient last visit' milestoneAug 14, 2025
• Lexaria provides positive interim results from partial 8-week data in Phase 1b GLP-1-H24-4 studyJul 28, 2025
• Lexaria’s study supports FDA registration path for oral DehydraTECH-Liraglutide capsuleJun 12, 2025